The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports.

Short interest in Nektar Therapeutics (NASDAQ:NKTR) decreased during the last reporting period, falling from 7.76M to 7.31M. This put 5.08% of the company's publicly available shares short.